NCT04590430 - Study to Assess the Safety, Tolerability, and Pharmacokinetics of HFB30132A Against COVID-19 in Healthy Adults | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 20, 2020

Primary Completion Date

July 26, 2021

Study Completion Date

July 26, 2021

Conditions

Healthy

Interventions

DRUG

HFB30132A

Participants randomized to HFB30132A will be administered dose 1 in cohort 1. Participants in Cohort 2 and 3 will receive HFB30132A doses 2 and 3, respectively.

OTHER

Placebo

Participants randomized to placebo will receive the same volume of solution as participants on active treatment.

Trial Locations (1)

45227

Medpace Clinical Pharmacology Unit, Cincinnati